Advisor Resource Council Makes New Investment in Gilead Sciences, Inc. (NASDAQ:GILD)

Advisor Resource Council purchased a new position in Gilead Sciences, Inc. (NASDAQ:GILD) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 4,441 shares of the biopharmaceutical company’s stock, valued at approximately $372,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in GILD. nVerses Capital LLC purchased a new position in Gilead Sciences in the 3rd quarter worth approximately $25,000. Valued Wealth Advisors LLC raised its stake in shares of Gilead Sciences by 101.9% in the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 161 shares during the last quarter. CarsonAllaria Wealth Management Ltd. lifted its holdings in shares of Gilead Sciences by 198.3% during the second quarter. CarsonAllaria Wealth Management Ltd. now owns 358 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 238 shares in the last quarter. Strategic Investment Solutions Inc. IL purchased a new stake in shares of Gilead Sciences during the second quarter valued at $33,000. Finally, Cedar Wealth Management LLC increased its holdings in Gilead Sciences by 51.6% in the 2nd quarter. Cedar Wealth Management LLC now owns 470 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 160 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insider Buying and Selling

In other Gilead Sciences news, insider Merdad Parsey sold 25,590 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $91.50, for a total value of $2,341,485.00. Following the sale, the insider now owns 99,599 shares of the company’s stock, valued at $9,113,308.50. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other Gilead Sciences news, insider Johanna Mercier sold 29,357 shares of the firm’s stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $83.78, for a total value of $2,459,529.46. Following the completion of the sale, the insider now owns 78,127 shares of the company’s stock, valued at $6,545,480.06. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Merdad Parsey sold 25,590 shares of the firm’s stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $91.50, for a total value of $2,341,485.00. Following the sale, the insider now directly owns 99,599 shares of the company’s stock, valued at $9,113,308.50. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 62,437 shares of company stock worth $5,374,825. Corporate insiders own 0.29% of the company’s stock.

Wall Street Analysts Forecast Growth

GILD has been the topic of several research analyst reports. BMO Capital Markets upped their target price on shares of Gilead Sciences from $94.00 to $102.00 and gave the company an “outperform” rating in a research note on Thursday. Royal Bank of Canada raised their target price on shares of Gilead Sciences from $75.00 to $81.00 and gave the stock a “sector perform” rating in a report on Thursday. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a research note on Thursday. Robert W. Baird raised their price target on Gilead Sciences from $80.00 to $95.00 and gave the stock a “neutral” rating in a research note on Thursday. Finally, JPMorgan Chase & Co. upped their price objective on Gilead Sciences from $100.00 to $105.00 and gave the company an “overweight” rating in a research report on Thursday. Eleven research analysts have rated the stock with a hold rating, eleven have given a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $90.05.

Gilead Sciences Stock Up 6.8 %

NASDAQ GILD opened at $97.90 on Friday. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $98.32. The company has a current ratio of 1.14, a quick ratio of 0.95 and a debt-to-equity ratio of 1.18. The stock has a market cap of $121.88 billion, a PE ratio of 119.39, a P/E/G ratio of 3.13 and a beta of 0.17. The stock’s 50 day moving average is $84.58 and its 200 day moving average is $74.67.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, topping analysts’ consensus estimates of $1.58 by $0.44. The firm had revenue of $7.55 billion during the quarter, compared to analyst estimates of $7.01 billion. Gilead Sciences had a net margin of 3.79% and a return on equity of 29.34%. Gilead Sciences’s revenue for the quarter was up 7.0% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.29 earnings per share. Research analysts predict that Gilead Sciences, Inc. will post 3.75 EPS for the current fiscal year.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.